January 1, 2022Open Access

Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer

Key points are not available for this paper at this time.

This study received funding from Reveal Genomics, IDIBAPS and the University of Padova.

AI에게 질문

Bookmark

View Full Paper

AI에게 질문

Bookmark

View Full Paper

Cite This Study